In 2023, the antidepressant medicine sales in Australia stood at AUD 558 million. Over the past two years, the market witnessed a year-on-year growth rate of 0.55% in 2022 and 1.09% in 2023. The Compound Annual Growth Rate (CAGR) over the last five years was 4.63%, indicating a stable upward trend in the market. This suggests a steady recovery and growth following previous fluctuations observed between 2013 and 2019.
Looking ahead, from 2024 to 2028, the market is forecasted to grow at a CAGR of 0.77%, with an overall growth rate of 3.89% within these five years. This projects a moderately positive outlook for the industry, albeit at a slower pace compared to previous years.
Future trends to watch for:
- Increased focus on mental health awareness and acceptance, likely boosting demand for antidepressant medications.
- Potential introduction of new, innovative antidepressant treatments and technologies that could alter market dynamics.
- Public and private healthcare policies that impact the accessibility and affordability of these medications.
- Possible effects of socioeconomic factors or global events on mental health and, consequently, on the sales of antidepressant medicines.
